Eli Lilly and Company (NYSE:LLY) Trading 1.6% Higher – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price traded up 1.6% during trading on Monday . The stock traded as high as $1,182.73 and last traded at $1,149.3790. 4,442,058 shares were traded during mid-day trading, an increase of 38% from the average session volume of 3,218,490 shares. The stock had previously closed at $1,131.42.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY received an FDA approval for extended EBGLYSS maintenance dosing in atopic dermatitis, allowing patients to use one injection every eight weeks instead of monthly. That could improve convenience and adherence while strengthening the drug’s commercial appeal. Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
• Positive Sentiment: The company also announced a national campaign for Zepbound with Shaquille O’Neal, highlighting obstructive sleep apnea treatment awareness and potentially boosting visibility for one of Lilly’s most important growth products. Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
• Positive Sentiment: Investor sentiment remains strong because Lilly is still seen as the leader in the booming GLP-1 obesity-drug market, with recent reports saying it has stayed ahead of rivals even as more competitors enter the space. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Analysts remain constructive, with Jefferies lifting its price target to $1,350 and maintaining a Buy rating, reinforcing the view that Lilly’s pipeline and obesity leadership can support more upside. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Neutral Sentiment: Lilly also expanded its Alzheimer’s pipeline through a licensing deal with AlzeCure, a long-term strategic move that adds optionality but is too early-stage to affect near-term earnings. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
• Neutral Sentiment: Broader market rotation into healthcare and defensive names has also helped support the stock, as investors pull back from tech and semiconductors. Zacks Investment Ideas feature highlights: Eli Lilly, Home Depot, Procter & Gamble and Starbucks

Analyst Ratings Changes

Several equities research analysts recently commented on LLY shares. Daiwa Securities Group boosted their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Finally, Barclays boosted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Stock Down 0.5%

The business has a fifty day simple moving average of $984.90 and a two-hundred day simple moving average of $1,014.46. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.07 trillion, a PE ratio of 40.45, a price-to-earnings-growth ratio of 1.26 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $30,000. Finally, 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.